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RESEARCH ARTICLE Open Access
Imaging for Dupuytren disease: a
systematic review of the literature
Sanne Molenkamp*, Roel J. M. van Straalen, Paul M. N. Werker and Dieuwke C. Broekstra
Abstract
Background: As treatment of Dupuytren disease (DD) is expected to shift towards prevention of progression, the
use of imaging in patients with DD becomes more important. In this systematic review an overview is given of the
different methods for and applications of imaging for DD that have been described.
Methods: The MEDLINE and EMBASE databases were searched for articles reporting the use of imaging in patients
with DD, published before May 17, 2018. Studies were systematically examined in two rounds by two observers
according to the PRISMA systematic. All studies containing original data on imaging for DD were considered for
inclusion.
Results: Three hundred and seven unique studies were identified, of which 23 were included in the study. Only
studies on the use of ultrasound (US) and magnetic resonance imaging (MRI) were identified. Broadly, articles could
be divided into 5 categories. Seven studies were found on diagnosis, two on measurement of disease extent, four
on measurement of disease activity, seven on guidance of minimally invasive procedures and five studies on
evaluation of treatment. According to the Oxford CEBM, the levels of evidence were low, ranging from level 3 to 5.
Conclusions: A variety of applications for US and MRI for patients with DD has been described. Based on the results of
this review, the largest value for imaging lies in the measurement of disease activity and the follow-up of treatment of
patients with early stage disease. Unfortunately, the overall level of evidence of the available literature was low. Future
research is necessary to define the exact value of US and MRI in the management of patients with DD.
Keywords: Dupuytren contracture, Ultrasonography, Magnetic resonance imaging, Imaging, Systematic review
Background
Dupuytren disease (DD) is a benign fibromatosis of the
palmar fascias of the hand. Much has been speculated
about the aetiology of DD and about why some patients
have a more aggressive course of the disease than others.
Both intrinsic and extrinsic factors, such as age, gender,
genetic predisposition, co-morbidity, manual labour and
hand-trauma, seem to play a role [1–5]. However, despite
the increase in knowledge on risk-factors and predictors
for the origin and progression of DD, the disease course
remains extremely variable [6, 7]. While some patients
require frequent operations to maintain functionality of
affected hands, some remain stable after one operation,
while others only develop nodules without any relevant
complaints. This is why it is essential that in the future,
evaluation and treatment of DD should be focused more
on the individual, based on genetic predisposition, envir-
onmental factors and clinical features [8, 9]. Ideally, an
individualized algorithm for DD will enable the differenti-
ation of patients with slow progression and a good prog-
nosis from patients that are at risk of aggressive disease,
who have to be monitored closely and treated at the right
moment using the most appropriate treatment. Such an
algorithm would assist in the selection of the most appro-
priate treatment, which range from non-invasive (pharma-
cotherapy, radiotherapy or splint therapy), to minimally
invasive (percutaneous needle fasciotomy (PNF) or Collage-
nase Clostridium Histolytocum (CCH) injections) to more
invasive (limited fasciectomy or dermatofasciectomy).
Currently, physical examination of the hands is the
gold standard for assessment of disease stage, disease ex-
tent and disease progression [10]. However, physical
examination only gives us at best a two-dimensional idea
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of the extent of disease. Also, with physical examination
disease activity can only be determined by performing
follow-up in time. An alternative to measure disease ac-
tivity, is by what the patient reports. However, the reli-
ability of this method is questionable as it is subjective.
Finally, physical examination cannot always give us reli-
able information about changes in anatomy (e.g. dis-
placed neurovascular bundles). The introduction of
imaging for DD could therefore be an important exten-
sion to the development of an individualized treatment
algorithm and to the improvement of the predictability
of results of existing treatment modalities. Ultrasound
(US) depicts echogenicity and is well suited to reveal di-
mensions of a soft tissue lesion in the sagittal and trans-
verse plane. With computed tomography (CT) and
magnetic resonance imaging (MRI) three dimensions of
soft tissue laesions can be displayed in detail. However,
the use of MRI is more common, as there is no add-
itional radiation exposure. All three imaging modalities
can give additional information about vascularity, size
and location [11–14].
The literature on the use of imaging to facilitate clin-
ical examination and treatment of patients with varying
stages of DD, is expanding [15]. However, no overview
of the possible applications of imaging for DD is avail-
able yet, which is why this systematic review was con-
ducted. The aim was to investigate what applications
have been described previously for different imaging mo-
dalities and DD, hereby also pointing out the topics that
are in need of further research.
Methods
A systematic literature search was performed on May 17,
2018 to identify articles on the use of ultrasound (US),
magnetic resonance imaging (MRI) and/or computed
tomography (CT)/positron emission tomography (PET)
for patients with DD. The MEDLINE and EMBASE data-
base were searched for relevant articles using the queries
reported in Table 1. These queries were created together
with an information specialist at our medical library.
Two independent observers (S.M. and R.v.S.) assessed
the articles in two assessment rounds. In the first round
the titles, abstracts and keywords were screened for the
combination of DD and US/MRI/CT/PET. For the
full-text round, articles were assessed for the use of im-
aging for DD. Articles on therapeutic ultrasound, also
known as shockwave therapy were excluded. When stud-
ies mentioned the use of imaging merely for the investi-
gation of post-operative complications of surgery for DD
(e.g. flexor tendon ruptures) and not for the
post-operative follow-up of Dupuytren tissue, they were
also excluded. As the aim of this study was to generate
an overview of the possible applications of imaging for
DD, all studies containing original data were considered
for inclusion, including case-reports and conference pro-
ceedings. The inclusion and exclusion criteria are shown
in Table 2. If consensus between the two observers could
not be reached, a third observer (D.C.B.) was consulted.
All included articles were assessed for level of evidence,
using the Oxford CEBM Levels of Evidence [16]. This
systematic review was written according to the PRISMA
reporting guideline for systematic reviews [17].
Results
The initial search yielded 307 unique studies. Of these
studies, 244 studies were excluded during the first
round. After assessment of the remaining 63 studies in
the second round, 23 studies were included in our study.
All studies described the use of US and/or MRI. Studies
on PET/CT were not found. The process of article selec-
tion is shown in Fig. 1.
Five different applications of US and/or MRI for DD
patients were identified: diagnosis, measurement of dis-
ease extent, measurement of disease activity, guidance of
minimally invasive procedures and evaluation of
treatment.
Diagnosis
Seven articles were found that report the use of US and/
or MRI for diagnosing DD (Table 3).
Five studies described the use of US and/or MRI for
the diagnosis of patients with DD, that had an atypical
presentation [18–22]. In two cases, US and MRI did not
lead to a diagnosis prior to surgery and DD was diag-
nosed upon histology [19, 21]. In the other three
case-report US and/or MRI led to a wrong diagnosis
prior to surgery and histology showed that the final diag-
nosis was DD [18, 20, 22].
In the two other studies, US was used to diagnose DD
in patients with a more typical presentation, in which
US was helpful in confirming the diagnosis that was
based on clinical examination [23, 24].
In summary, imaging was not instrumental in diagnos-
ing DD in any of the patients with an atypical
Table 1 Search strategy per database
Database Search query
MEDLINE (“Dupuytren Contracture”[Mesh] OR dupuytren*[tiab] OR
palmar fibromatos*[tiab]) AND (“Ultrasonography”[Mesh] OR
“ultrasonography” [Subheading] OR “Tomography”[Mesh] OR
ultraso*[tiab] OR “radiography” [Subheading] OR
echograph*[tiab] OR radiograph*[tiab] OR tomograph*[tiab]
OR sonograph*[tiab] OR CT [tiab] OR PET [tiab] OR MRI [tiab]
OR imaging [tiab])
EMBASE (‘dupuytren contracture’/exp. OR dupuytren*:ab,ti OR ‘palmar
fibromatosis’:ab,ti) AND (‘echography’/exp. OR
‘radiodiagnosis’/exp. OR ultraso*:ab,ti OR echograph*:ab,ti OR
radiograph*:ab,ti OR tomograph*:ab,ti OR sonograph*:ab,ti OR
ct:ab,ti OR pet:ab,ti OR mri:ab,ti OR imaging:ab,ti)
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presentation, but did assist in the diagnosis of DD in pa-
tients with a more typical presentation.
Measurement of disease extent
Two studies described the use of MRI to measure dis-
ease extent (Table 4). The first was a case-report in
which MRI displayed characteristic features regarding
signal intensity and demonstrated the severity and depth
of the different fibromatoses (including DD) [25]. Ac-
cording to the authors, MRI is the best imaging modality
to delineate the margins and depth of soft-tissue inva-
sion of these lesions and that it can be helpful in guiding
appropriate clinical management. The other study was a
prospective case-series in which MRI was used to assess
11 hands of 10 patients with DD, that were scheduled
for fasciectomy [26]. MRI accurately detected 96% of the
cords and 93% of the nodules prospectively, confirmed
by surgery and pathology. One cord that was missed,
was detected post hoc. One nodule that was missed, was
not detected post hoc because it was small and could
not be distinguished from a cord. Disease extent corre-
sponded closely to the surgical and gross pathological
findings.
These studies show that MRI can accurately assess dis-
ease extent. However, for US it is unknown, as there
were no available studies on the use of US to measure
disease extent.
Measurement of disease activity
Three studies reported the use of US or MRI to measure
disease stage of DD, of which 2 report on findings using
US (Table 5). One was a case-report in which Dupuytren
tissue was highly vascular and had mixed echogenicity,
which were interpreted by the authors as signs of early
DD [27]. Furthermore, US-elastography, which can
evaluate the elasticity of soft tissues, showed that the
thickened aponeurosis and nodules had a firm structure
compared to the surrounding tissue. According to the
authors, US-elastography could be a potential diagnostic
for the differentiation between acute and chronic DD
findings. In the second study, a cohort of DD patients,
undergoing either enzymatic lysis with CCH-injections
or PNF, was followed prospectively [28]. Prior to
Table 2 Inclusion and exclusion criteria used in different rounds
Round 1: Title + abstract Round 2: Full-text
Inclusion criteria Inclusion criterion
- Patients with DD Imaging (US/MRI/CT/PET)
used for the
- Imaging (US/MRI/CT/PET) assessment of DD
Exclusion criteria Exclusion criteria
- Language other than Dutch,
English, German or French
- Ultrasonic therapy for DD
- No original data - Imaging for post-operative
complications
- No original data
DD Dupuytren Disease, US ultrasound, MRI magnetic resonance imaging, CT
computed tomography, PET positron emission tomography
Fig. 1 Flow-chart of process of article selection
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treatment, the cords of 38 patients were classified with
US as either nodular or fibrillar and were assessed for
echogenicity (hyper, iso or mixed). Twenty-four (64%)
cords had mixed echogenicity and no hypo-echogenic
cords were found. After 2 years, 21 (54%) of the patients
retained a straight finger, without the formation of a
new cord. Fourteen patients (53%) with a nodular cord
and 1 patient (17%) with a fibrillary cord had signs of re-
sidual or recurrent disease after 2 years. Three patients
with signs of residual disease had a recurrent
contracture, all of these patients had nodular cords with
mixed echogenicity.
The third study described the use of MRI to meas-
ure disease stage by correlating MRI signal intensity
to histological results [26]. In total, 22 cords and 13
nodules were found. In all cords and nodules, a low
to intermediate signal intensity corresponded to low
cellularity and an intermediate to high signal inten-
sity corresponded to high cellularity or mixed
composition.
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These studies suggest that echogenicity/elasticity and
MRI signal intensity are a reflection of disease activity,
of which the last two studies have substantiated this hy-
pothesis with study results.
Guidance of minimally invasive procedures
Seven studies described the use of pre- or peri-operative
US for enhancement of safety and improvement of out-
comes of minimally invasive procedures (Table 6). Three
studies focused on pre-operative detection of displaced
neurovascular (NV) bundles using Doppler-US, which
focuses on blood flow of the digital artery [29–31]. In
two studies, US was used to prospectively detect dis-
placed NV-bundles in several patients with severe
Dupuytren contractures undergoing fasciectomy [29,
30]. The surgical findings all corresponded to the US
findings in these studies. In the third study, US was used
to prospectively detect a displaced NV-bundle in a co-
hort 48 DD patients undergoing PNF [31]. When a dis-
placed NV-bundle was detected, the site was marked
and during the procedure the needle was inserted prox-
imal or distal to the marked site. There was no instance
of post-operative neurovascular dysfunction.
Four other studies performed ultrasound guided pro-
cedures [32–35]. The first showed the results of a
patient undergoing US-guided PNF followed by osteo-
pathic manipulative treatment [32]. The patient did not
experience post-operative complications. The second
study prospectively followed the results of US-guided
CCH injections in a cohort of 33 DD patients [35]. No
flexor tendon ruptures or damages to the NV-bundle
were reported. In the last two studies, by the same au-
thors, complications of a variety of US guided proce-
dures in the hand were evaluated. These studies have
suspected data-overlap, however, since the research
question differed and no meta-analysis is conducted with
the data, we decided to include both studies. In the first
study, 513 procedures in 402 patients were conducted,
of which 105 were Dupuytren contractures [34]. No in-
stance of tendon-rupture or damage to the NV-bundle
was reported in the whole group. In the other study, 63
US-guided procedures were conducted in 43 patients on
anti-coagulants, of which 12 were Dupuytren contrac-
tures [33]. The anti-coagulants were not interrupted and
local anaesthesia with epinephrine was used. No instance
of clinically relevant hematoma was reported.
The conclusion of these articles is that US guided min-
imally invasive surgery is safe and result are satisfactory.
However, none of these studies used a control group,
which is why the additional value of US cannot be
determined.
Evaluation of treatment
Five studies reported the use of US or MRI to evaluate
different operative and non-operative treatment modal-
ities (Table 7). Three studies used US or MRI to
Table 5 Summary of studies on imaging for measurement of disease activity
Author
(year)
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follow-up non-invasive treatment [36–38]. In the first
study, US was used to follow-up cross-frictional treat-
ment of a patient with early stage DD, which is a therapy
that aims to reduce contracture by stretching the
Dupuytren tissue [36]. US imaging was unable to detect
any changes to the subcutaneous features of the contrac-
tures after 8 weeks of treatment. In the second study, tri-
amcinolone acetonide injections were given in 37 DD
Table 6 Summary of studies on imaging for pre and peri-operative guidance of minimally invasive procedures
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patients with 49 hands affected with early stage nodules
[37]. The injected nodules were assessed with US for size
in the sagittal plane prior to injection and were followed
with US for 5 years. A significant decrease in size was
detected from pre-injection to 6 months follow-up and
to the final follow-up. In the third study, MRI was used
to follow-up size and signal intensity of superficial fibro-
matoses of the hands and feet in patients undergoing
electron beam therapy (EBT) [38]. Intensity decreased
significantly, which was attributed to progression from
the proliferative to the residual stage. Mean volume also
decreased significantly. Furthermore, patients with the
highest pre-treatment intensity score had the biggest de-
crease in VAS pain scale.
Two studies used US or MRI for the follow-up of min-
imally invasive procedures. In the first study, gap width
of ruptured cords was evaluated with US, following
CCH or PNF [39]. In all patients undergoing PNF and in
80% of patients undergoing CCH a single gap was de-
tectable at the injection site and there was no significant
difference in gap width between the groups. Further-
more, post-operative outcome, with a follow-up of 1
year, was comparable in the two groups. In the second
study, MRI was used to evaluate if CCH disrupts or di-
gests the Dupuytren cord [40]. Five patients were exam-
ined and MRI showed that signal intensity of the
injected cords increased significantly, most likely be-
cause of tissue reaction to the injected CCH. Further-
more, the volume of a Dupuytren cord decreased
significantly at 30 days post-injection. In summary, US
and MRI were both used for the follow-up of different
treatment modalities and a variety of outcome parame-
ters was measured following treatment, like volume, sig-
nal intensity and gap-width of a cord.
Discussion
With the current evolution in the knowledge of DD, it is
likely that treatment will move towards a more individual-
ized algorithm [8]. Instead of just aiming at reduction of
contractures in patients with an advanced stage of the dis-
ease, the ultimate goal is to develop a strategy that can dis-
tinguish between benign forms of DD, with no or hardly
any progression, and more severe forms that do progress.
Within the latter group, such a strategy would enable us to
differentiate patients that will only need treatment once
from the most severe cases that are at risk of rapid progres-
sion and recurrence after treatment. Especially for this last
category, efforts should be made to create a therapy that
prevents progression (eg. anti-inflammatory drugs,
anti-mitotic drugs, radiotherapy) [41–44]. With this on-
going evolution in treatment of DD, there is need for reli-
able instruments that can assess and monitor disease
activity and measure disease extent. This is particularly
relevant for patients with early stage, active disease that
may be eligible for preventive treatment. It is suggested that
imaging may be able to play a role here, especially in the
evaluation of disease activity, for which no other outcome
measure is currently available [11, 26]. This systematic re-
view aimed to investigate the current knowledge of imaging
for DD and for what purposes imaging in patients with DD
has been used.
Only studies on the use of US and MRI were found
and no studies on the use of CT. A variety of applica-
tions for the use of US and MRI for DD was found,
which could broadly be divided in 5 categories: diagno-
sis, measurement of disease extent, measurement of dis-
ease activity, guidance of minimally invasive procedures
and evaluation of treatment.
Diagnosis
As pointed out in the introduction, DD is usually diag-
nosed by physical examination [10]. However, in all
case-reports that described the use of US and/or MRI
for the diagnosis of DD because of an atypical presenta-
tion, histology was required to make a final diagnosis,
which is the gold standard [18–22]. This implies that US
and MRI cannot differentiate DD from other soft tissue
diseases to set the diagnosis. However, this can also be a
reflection of the lacking knowledge of typical imaging
features that characterise DD on US and MRI.
Furthermore, two studies concluded that US may be
helpful in supporting the diagnosis for patients with a
more typical presentation of DD [23, 24]. However, it is
questionable if US is of additional value when clinical
signs of the disease are evident.
In our opinion, imaging should still be performed for
certain patients, to acquire additional information such
as extent, dimensions and affection of neighbouring
structures of an undefined lesion, but there is no place
for routine imaging in the diagnosis of DD.
Measurement of disease extent
Two studies point out that MRI can accurately measure dis-
ease extent of DD [25, 26], which may be valuable in clinical
management. However, at present, the choice of surgery is
not primarily based on the extent of the disease, but more
on the severity of contracture and patient complaints, which
can also be monitored using physical examination [10, 45].
This is why the use of MRI for measurement of disease ex-
tent seems to be a cost-ineffective method to add to regular
monitoring of patients with DD.
Measurement of disease stage
Several studies hypothesise that there is a relation be-
tween echogenicity and signal intensity of Dupuytren tis-
sue and disease stage [26–28]. If US and MRI are indeed
able to reflect cellularity of nodules and cords and
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hereby disease stage, this would be of importance in the
monitoring of patients with early disease.
However, the overall evidence is poor. One study re-
ports on the use of US-elastography and hypothesizes
that it may differentiate both the acute and chronic find-
ings in DD [27]. Unfortunately, this study comprised of
only one patient and results were not substantiated with
histology or follow-up. Another study concluded that
echogenicity of Dupuytren cords may be a related to re-
currence [28]. However, the inter-rater reliability of
assessing nodularity of cords was poor (Cohen’s kappa =
0.38). Also, the authors did not conduct any statistical
analyses to show a significant difference in the
occurrence of recurrence between fibrillar and nodular
cords. Finally, no clear definition of recurrence was used
in this article. Recurrence was defined as either residual
disease (a palpable cord without recurrent contracture)
or recurrent contracture. In our opinion this definition
is nonspecific, as DD tissue is not excised during
CCH-injections and PNF, which is why it is expected
that most patients have signs of residual disease. Recur-
rent contracture is more clinically relevant, but for this
outcome parameter no cut-off value was described. The
relation between echogenicity and activity of a DD nod-
ule has also been reported in a descriptive article by Cré-
teur et al. [11]. This article was not included in the
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analyses since the conclusions were based on an expert
opinion of the author and no patient data were
provided.
The final study in this category showed that MRI sig-
nal intensity corresponds to disease stage, which was de-
termined using the gold standard histology [26]. These
results seem promising, however, as US is easier to ac-
cess, less expensive and patient-friendlier than MRI, it
would be very interesting to investigate if echogenicity
also corresponds to cellularity in the future. If this is the
case, US can be used regularly to assess if patients are at
risk of an aggressive course of DD, which is helpful in
disease monitoring and in the future also for the selec-
tion of patients that are eligible for treatment aiming at
disease control [41, 46].
Guidance of minimally invasive procedures
The main reason to perform US-guided minimally inva-
sive procedures is to enhance safety. In addition to that
US-guidance may optimize results. The available litera-
ture showed that displaced NV-bundles could be de-
tected using (Doppler)-US [29, 30] and that US-guided
minimally invasive surgery had a low complication rate
(no incidence of flexor tendon rupture or damage to
NV-bundle) [31–35]. Furthermore, ultrasound guided
procedures had satisfactory results [31, 32, 35]. However,
no study used a control group of patients undergoing
non-US-guided minimally invasive surgery. When com-
paring the results to studies that did not perform US,
there does not seem to be much difference in both com-
plication rate and reduction of contracture [47–54]. A
randomized controlled trial should be conducted to ana-
lyse whether US is really of additional value in pre- and
peri-operative management.
Evaluation of treatment
The last application that was described for US and MRI,
was evaluation of several treatment modalities. The number
of studies reporting the outcomes of non-surgical treatment
aiming at disease control of patients with early DD is in-
creasing [41, 55]. As these patients do not have contractures
yet, there is need for an alternative reliable outcome param-
eter. This is why several studies report the use of imaging to
follow-up treatment outcome of non-surgical procedures for
patients with early DD [36–38]. In our opinion, the use of
US and MRI to follow-up size and signal of early DD nod-
ules is most relevant as, currently, the only other reliable
measurement instruments for patients without contractures
is physical examination, which only measures area of disease
in one plane and measures the projection of DD on the
overlying skin [10]. However, no information on the reliabil-
ity of these imaging modalities for the measurement of area
of early DD is available yet. Studies covering the reliability of
multiple measurements by a single observer (intra-observer
reliability) and measurements by multiple observers (inter--
observer reliability) have to be conducted first, to determine
the accuracy of US and MRI in the measurement of disease
extent in patients with early DD.
Furthermore, imaging for the follow-up of minimally in-
vasive surgery in patients with contractures was described
[39, 40]. The results of follow-up of CCH-injections were
contradicting. While one study observed an overall de-
crease of the DD cords [40], the other study observed a
local disruption at the injection site comparable to that of
PNF [39]. This may be caused by the difference in
follow-up time and also by the different imaging modality
used (MRI vs US). A study measuring cord volume mul-
tiple times following PNF and CCH-treatment could give
more insight. However, the relevance of such a study is
questionable as there was no difference in surgical out-
come and recurrence between PNF and CCH [39], which
is supported by previous literature on the outcomes of
CCH-injection vs PNF [56].
Limitations
Generating a clear overview about imaging for DD was
challenging, as there was a wide variety of described ap-
plications and overall the included studies had a low
level of evidence. Ten studies were case-reports, includ-
ing only 1 patient [18–23, 25, 27, 32, 36]. In three other
studies, less than 10 DD patients were included [24, 38,
40] and in one study the number of observed patients
was not described [29]. Of the 9 other studies that did
describe a larger cohort of DD patients [26, 28, 31, 35,
37, 39], two studies were conference proceedings [33,
34] and only 1 study included a control group with
healthy volunteers for a part of the study [30]. All stud-
ies were observational, and most lacked adequate statis-
tical methods. The median level of evidence was 4, and
no randomized controlled trials were found.
The inclusion of case-reports and conference proceed-
ings may also be seen as weakness of this study. How-
ever, as this is the first systematic review on imaging for
DD specifically, it was of interest to include as many
studies as possible that showed original data, so that the
provided information was as complete as possible. Al-
though the search string that was used was selected to
be inclusive, it is possible that some studies were not
found by our review. Some studies may have used im-
aging, but not mentioned this in the title, abstract or
keywords. However, because of this it is unlikely that
these studies aimed to emphasize the value of imaging
for DD. Also, we decided to exclude review articles. Al-
though some of these articles did show original US/
MRI-images of patients with DD [11–13, 57–67], no ori-
ginal data on one of the possible applications of imaging
for DD were given in these articles or the information
provided was based on an expert opinion.
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Another limitation is that there is a risk of publication
bias. Studies that found a valuable application of imaging
for DD are more likely to be published than studies that
did not show any relevant findings. Finally, relevant arti-
cles may have been missed because they were excluded
based on language.
Conclusions
Despite the variety of study designs and overall low level
of evidence of the available literature, our review shows
that there are interesting applications for imaging in the
management of DD patients. The greatest value of im-
aging seems to lie in the monitoring of disease activity
and outcome of non-surgical treatments for patients
with early disease. As mentioned in the introduction,
treatment of DD patients is currently predominantly
aimed at correction of contractures. But when looking at
the literature, the focus of research is moving towards
the prevention of contractures in patients with early DD
and the creation of an individualized treatment algo-
rithm [8, 41, 55]. For the development of treatment aim-
ing at disease control, a reliable outcome measure that
can provide information about disease stage and extent
in patients with early disease is required. If further re-
search proves that disease activity can be measured with
imaging, and with US in particular as it is less expensive
and easier to access, it could be a part of the regular
monitoring of DD patients. However, before US can be
implemented for this purpose, the hypothesis that echo-
genicity corresponds to cellularity needs to be substanti-
ated by histological results. Also, agreement-studies on
the reliability of US for the measurement of early DD
have to be conducted.
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